InsiderTrades.com logo
Carl L. Gordon net worth and biography
  • LinkedIn
  • Phone
  • Website

Carl Gordon Biography and Net Worth

Director of Scribe Therapeutics

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. For the last six years (2014 to 2019) Forbes(R) Magazine named Dr. Gordon one of the top 100 venture capitalists in the world when it placed him on the "Forbes Midas List". He received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987), and was a Fellow at The Rockefeller University from 1993 to 1995.

What is Carl L. Gordon's net worth?

The estimated net worth of Carl L. Gordon is at least $89.57 million as of August 10th, 2026. Mr. Gordon owns 2,714,279 shares of Scribe Therapeutics stock worth more than $89,571,207 as of September 18th. This net worth evaluation does not reflect any other investments that Mr. Gordon may own. Learn More about Carl L. Gordon's net worth.

How do I contact Carl L. Gordon?

The corporate mailing address for Mr. Gordon and other Scribe Therapeutics executives is 1150 Marina Village Pkwy, Alameda, CA, 94501. Scribe Therapeutics can also be reached via phone at (510) 454-0213. Learn More on Carl L. Gordon's contact information.

Has Carl L. Gordon been buying or selling shares of Scribe Therapeutics?

During the last quarter, Carl L. Gordon has bought $15,000,000.00 in shares of Scribe Therapeutics stock. Most recently, on Monday, July 27th, Carl L. Gordon bought 1,000,000 shares of Scribe Therapeutics stock. The stock was acquired at an average cost of $15.00 per share, with a total value of $15,000,000.00. Following the completion of the transaction, the director now directly owns 1,348,825 shares of the company's stock, valued at $20,232,375. Learn More on Carl L. Gordon's trading history.

Who are Scribe Therapeutics' active insiders?

Scribe Therapeutics' insider roster includes Behzad Aghazadeh (Director), Carl Gordon (Director), and David Parrot (CFO). Learn More on Scribe Therapeutics' active insiders.

Are insiders buying or selling shares of Scribe Therapeutics?

During the last year, Scribe Therapeutics insiders bought shares 5 times. They purchased a total of 3,727,237 shares worth more than $56,291,746.20. The most recent insider tranaction occured on July, 28th when Director Behzad Aghazadeh bought 7,905 shares worth more than $144,266.25. Learn More about insider trades at Scribe Therapeutics.

Information on this page was last updated on 7/28/2026.

Carl L. Gordon Insider Trading History at Scribe Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2026Buy1,000,000$15.00$15,000,000.001,348,825View SEC Filing Icon  
See Full Table

Carl L. Gordon Buying and Selling Activity at Scribe Therapeutics

This chart shows Carl L. Gordon's buying and selling at Scribe Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scribe Therapeutics Company Overview

Scribe Therapeutics logo
Scribe Therapeutics Inc. is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc. is based in ALAMEDA, Calif.
Read More

Today's Range

Now: $33.00
Low: $31.76
High: $35.40

50 Day Range

MA: $26.95
Low: $18.06
High: $37.25

2 Week Range

Now: $33.00
Low: $17.31
High: $39.60

Volume

2,236,386 shs

Average Volume

210,506 shs

Market Capitalization

$624.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A